Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hMSC-Exos Nebulized Inhalation for ARDS
NCT04602104Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hMSC-Exos in acute respiratory distress syndrome (ARDS) (6 arms), sponsored by Ruijin Hospital. Primary endpoints: Incidence of adverse reaction at 14 days, Time to Clinical Improvement at 28 days and 1 more. Started Nov 2020; status: completed.
02
Drugs
hMSC-Exos
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04602104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602104.